Literature DB >> 9083034

The interaction between basic fibroblast growth factor and heparan sulfate can prevent the in vitro degradation of the glycosaminoglycan by Chinese hamster ovary cell heparanases.

S Tumova1, K J Bame.   

Abstract

Heparan sulfate proteoglycans on Chinese hamster ovary (CHO) cell surfaces can bind and internalize basic fibroblast growth factor (bFGF). We have investigated whether this interaction affects heparan sulfate catabolism in vitro by measuring the ability of partially purified CHO heparanase activities to degrade 35S-labeled heparan sulfate glycosaminoglycans in the absence or presence of bFGF. Our studies show that the presence of the growth factor prevents partially purified heparanases from degrading the nascent 81-kDa chains to short 6-kDa products, whether the glycosaminoglycan is free in solution or covalently bound to core proteins. A 30-60 molar excess of the growth factor is required to inhibit completely chain degradation by heparanases, implying that multiple bFGF molecules must be bound to the glycosaminoglycan to prevent heparanase-catalyzed catabolism. This hypothesis is supported by protection studies indicating that nascent CHO heparan sulfate glycosaminoglycans have at least four to eight bFGF binding sites/chain. It does not appear, however, that the growth factor inhibits heparanase-catalyzed degradation of the glycosaminoglycan by binding to the sequence cleaved by the enzyme. Both the nascent and short chains bind bFGF with similar affinity (Kd values of 27.0 +/- 3.5 and 38.9 +/- 5.1 nM, respectively), indicating that heparanase activities do not destroy the bFGF binding sites. Rather, our results suggest that the growth factor interferes sterically with heparanase action by binding the heparan sulfate chain at a sequence next to the cleavage site or at a secondary site recognized by the enzyme.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9083034     DOI: 10.1074/jbc.272.14.9078

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Characterization of a novel intracellular heparanase that has a FERM domain.

Authors:  Karen J Bame; Indumati Venkatesan; Jean Dehdashti; Jeffrey McFarlane; Rebecca Burfeind
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

2.  The heparin-binding domain of HB-EGF mediates localization to sites of cell-cell contact and prevents HB-EGF proteolytic release.

Authors:  Robin N Prince; Eric R Schreiter; Peng Zou; H Steven Wiley; Alice Y Ting; Richard T Lee; Douglas A Lauffenburger
Journal:  J Cell Sci       Date:  2010-06-08       Impact factor: 5.285

3.  Basic fibroblast growth factor does not prevent heparan sulphate proteoglycan catabolism in intact cells, but it alters the distribution of the glycosaminoglycan degradation products.

Authors:  S Tumova; B A Hatch; D J Law; K J Bame
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

4.  Compound heterozygous loss of Ext1 and Ext2 is sufficient for formation of multiple exostoses in mouse ribs and long bones.

Authors:  Beverly M Zak; Manuela Schuksz; Eiki Koyama; Christina Mundy; Dan E Wells; Yu Yamaguchi; Maurizio Pacifici; Jeffrey D Esko
Journal:  Bone       Date:  2011-02-15       Impact factor: 4.398

Review 5.  Heparan sulfate proteoglycans and their binding proteins in embryo implantation and placentation.

Authors:  Catherine B Kirn-Safran; Sonia S D'Souza; Daniel D Carson
Journal:  Semin Cell Dev Biol       Date:  2007-07-31       Impact factor: 7.727

6.  Partial purification of heparanase activities in Chinese hamster ovary cells: evidence for multiple intracellular heparanases.

Authors:  K J Bame; A Hassall; C Sanderson; I Venkatesan; C Sun
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

7.  A gradient of matrix-bound FGF-2 and perlecan is available to lens epithelial cells.

Authors:  Weiju Wu; Frederique M Tholozan; Martin W Goldberg; Leon Bowen; Junjie Wu; Roy A Quinlan
Journal:  Exp Eye Res       Date:  2013-12-14       Impact factor: 3.467

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.